Breaking Finance News

FBR Capital announced Shire PLC (ADR) (NDAQ:SHPG), boosting its stock price target to $201.00 today

In a report released on Thursday October 19, 2017 FBR Capital increased the stock price target of Shire PLC (ADR) (NDAQ:SHPG) to $201.00 reporting a possible upside of 0.36%.

Previously on 10/11/2017, RBC Capital Markets released a statement about Shire PLC (ADR) (NDAQ:SHPG) increased the target price from $0.00 to $213.00. At the time, this indicated a possible upside of 0.40%.

Just yesterday Shire PLC (ADR) (NDAQ:SHPG) traded -3.79% lower at $147.81. Shire PLC (ADR)’s 50-day moving average is $154.03 and its 200-day moving average is $164.51. The last stock price is down -11.07% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 2,220,913 shares of SHPG traded hands, up from an average trading volume of 1,206,980

Recent Performance Chart


Shire PLC (ADR) has 52 week low of $139.36 and a one year high of $192.64 with a PE ratio of 65.45 and has a market capitalization of $0.

A total of 14 analysts have released a report on Shire PLC (ADR). Seven analysts rating the company a strong buy, seven analysts rating the company a buy, two analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $241.86.

General Company Details For Shire PLC (ADR) (NDAQ:SHPG)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.